|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6400 - 0.6400|
|52 Week Range||0.4500 - 1.0000|
|Beta (3Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The announcement comes in anticipation of near-term FDA 510(k) fillings for Nu-Med Plus nitric oxide delivery devices. “We welcome Ms. Thomas to our company and we are certain she will provide highly valued insight and assistance navigating our company thru the FDA processes for new technologies.
SALT LAKE CITY, April 03, 2019 -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology, reports an increase in strategic.
SALT LAKE CITY, Feb. 05, 2019 -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology will receive its first clinical unit.
In it he writes about the untapped potential of inhaled nitric oxide. When delivered in precise doses, inhaled nitric oxide has already been proven to stabilize blood pressure, open airways, fight infections and blood clots, treat erectile dysfunction and combat aging. Robins writes about what he sees as a stagnated inhaled nitric oxide industry which he believes has not delivered on the full potential of the life-saving molecule, and “the true potential of nitric oxide has, I believe, been bottled up by one or two major corporations.
Nitric oxide is naturally occurring in blood and acts as a vasodilator by expanding and dilating blood vessels. According to recent studies1, the longer blood is stored, the more nitric oxide is depleted, increasing potential risks to patients such as hypoxia, infection, and heart failure.